Tryngolza is once-monthly, subcutaneous RNA-targeted therapy and is expected to be available by the end of the year with a ...

A new study shows that nearly 90% of patients with moderate-to-severe atopic dermatitis (AD) reported their condition ...

The new, now-defeated bill eliminated the PBM reform measures included in a larger spending bill that the president-elect and ...

Anna Podolanczuk, M.D., M.S., discusses how the mortality rates for patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) are impacted by comorbidities, including ...